Pro-Pe adhesive tablet
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ulcer, Aphthous
Conditions
Ulcer, Aphthous
Trial Timeline
— → May 1, 2007
NCT ID
NCT00281723About Pro-Pe adhesive tablet
Pro-Pe adhesive tablet is a phase 2 stage product being developed by Advanced Medical Solutions Group for Ulcer, Aphthous. The current trial status is active. This product is registered under clinical trial identifier NCT00281723. Target conditions include Ulcer, Aphthous.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00281723 | Phase 2 | Active |
Competing Products
20 competing products in Ulcer, Aphthous
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CHF6467 active | Comac Medical | Phase 1/2 | 33 |
| Mirikizumab SC + Mirikizumab IV + Placebo SC | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 2 | 52 |
| Azathioprine + Placebo | Celltrion | Approved | 85 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Tacrolimus | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + Placebo | Astellas Pharma | Phase 3 | 77 |
| E3810 + E3810 + Teprenone | Eisai | Phase 2/3 | 65 |
| Filgotinib Maleate | Eisai | Approved | 85 |
| AJM300 + Placebo | Eisai | Phase 3 | 77 |
| E0671 + rabeprazole sodium + E0671 placebo | Eisai | Approved | 85 |
| GSK3050002 + Placebo | Eisai | Phase 1 | 33 |
| Rabeprazole + Rabeprazole | Eisai | Phase 2/3 | 65 |
| adalimumab + placebo | Eisai | Phase 3 | 77 |
| E6007 + Placebo | Eisai | Phase 2 | 52 |
| Pariet | Eisai | Pre-clinical | 23 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 1 | 33 |
| Arm1 + Arm 2 | Zydus Lifesciences | Phase 2 | 52 |